EYE TECH CARE is a French ophthalmology company backed by private European and Chinese investors, founded in 2008. The company has developed EyeOP1?, a unique non-invasive medical device to treat glaucoma with ultrasound, based on a proprietary technology. Glaucoma is a chronic serious disease that affects over 90 million people worldwide, growing constantly due to aging population. The standard of care are eyedrops which often lose their therapeutic effect over time and surgery which in turn is related to significant risks of complications. EyeOP1? went through the clinical phase and has CE mark approval. Over 8,000 patients have been treated and over 100 clinical papers and abstracts were published. EYE TECH CARE has a dedicated commercial strategy for China with its 25 million glaucoma patients and where access and infrastructure for sophisticated glaucoma surgery is limited and patients present often with advanced disease stages. The company got registration from the Chinese FDA in October 2017 giving a significant competitive advantage as no other innovative product for glaucoma is approved in this market and EYE TECH CARE will have an estimated advance of 3 to 4 years. The company created a wholly owned subsidiary in Shanghai and built a commercial and clinical team with revenues entering since Q1/2018. Regional sales channels were set-up with distributors carefully selected and constantly on the spot for their performance. Thus, the team achieved in its first year of commercialization in China a broad success both in numbers and in brand awareness. Over 100 centers in China already treated over 1000 patients within product demonstrations, several EyeOP1 systems were commercially sold and the sales pipeline comprises over 130 top tear level hospitals. The majority of distributors that had been assigned to a total of 10 territories kept their commitments and the company set the course to continue strong growth and market penetration. While the company is focusing on growth in China, additional emerging markets are being addressed and the product is already approved in the Middle East, India, some South East Asian countries, and Mexico. The company is opening a new fund raising round to back-up growth in China and bridge the period until break-even in 2021/2022.,EYE TECH CARE is a French ophthalmology company backed by private European and Chinese investors, founded in 2008. The company has developed EyeOP1?, a unique non-invasive medical device to treat glaucoma with ultrasound, based on a proprietary technology. Glaucoma is a chronic serious disease that affects over 90 million people worldwide, growing constantly due to aging population. The standard of care are eyedrops which often lose their therapeutic effect over time and surgery which in turn is related to significant risks of complications. EyeOP1? went through the clinical phase and has CE mark approval. Over 8,000 patients have been treated and over 100 clinical papers and abstracts were published. EYE TECH CARE has a dedicated commercial strategy for China with its 25 million glaucoma patients and where access and infrastructure for sophisticated glaucoma surgery is limited and patients present often with advanced disease stages. The company got registration from the Chinese FDA in October 2017 giving a significant competitive advantage as no other innovative product for glaucoma is approved in this market and EYE TECH CARE will have an estimated advance of 3 to 4 years. The company created a wholly owned subsidiary in Shanghai and built a commercial and clinical team with revenues entering since Q1/2018. Regional sales channels were set-up with distributors carefully selected and constantly on the spot for their performance. Thus, the team achieved in its first year of commercialization in China a broad success both in numbers and in brand awareness. Over 100 centers in China already treated over 1000 patients within product demonstrations, several EyeOP1 systems were commercially sold and the sales pipeline comprises over 130 top tear level hospitals. The majority of distributors that had been assigned to a total of 10 territories kept their commitments and the company set the course to continue strong growth and market penetration. While the company is focusing on growth in China, additional emerging markets are being addressed and the product is already approved in the Middle East, India, some South East Asian countries, and Mexico. The company is opening a new fund raising round to back-up growth in China and bridge the period until break-even in 2021/2022.